Literature DB >> 11295379

Sustained and selective attention as measures of genetic liability to schizophrenia.

L A Jones1, A G Cardno, R D Sanders, M J Owen, J Williams.   

Abstract

We tested for a relationship between attention and genetic liability to schizophrenia. Samples of probands with DSM-IV schizophrenia (n=20), their well first-degree relatives (n=40) and healthy controls (n=82) were tested using measures of sustained attention (degraded-stimulus continuous performance test: DS-CPT) and selective attention (spatial negative priming task). Assuming a liability-threshold model, we predicted that probands would display greater attentional decrements than controls and that the relatives would show intermediate levels of decrement. We did not observe the predicted pattern of effect using either measure, although the probands showed a trend towards less negative priming. However, our results may have been affected by self-selection bias in probands and relatives and clinical heterogeneity among probands, which could have reduced our power to detect effects.

Entities:  

Mesh:

Year:  2001        PMID: 11295379     DOI: 10.1016/s0920-9964(00)00136-5

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  9 in total

1.  Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: influence of clozapine.

Authors:  David M Thomson; Allan McVie; Brian J Morris; Judith A Pratt
Journal:  Psychopharmacology (Berl)       Date:  2010-09-29       Impact factor: 4.530

2.  Attentional window in schizophrenia and schizotypal personality: Insight from negative priming studies.

Authors:  Randall K Minas; Sohee Park
Journal:  Appl Prev Psychol       Date:  2007-12

3.  Attention/vigilance in schizophrenia: performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS).

Authors:  Keith H Nuechterlein; Michael F Green; Monica E Calkins; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Laura C Lazzeroni; Gregory A Light; Allen D Radant; Larry J Seidman; Larry J Siever; Jeremy M Silverman; Joyce Sprock; William S Stone; Catherine A Sugar; Neal R Swerdlow; Debby W Tsuang; Ming T Tsuang; Bruce I Turetsky; David L Braff
Journal:  Schizophr Res       Date:  2015-03-04       Impact factor: 4.939

4.  Fine motor function and neuropsychological deficits in individuals at risk for schizophrenia.

Authors:  Ute Gschwandtner; Marlon Pflüger; Jacqueline Aston; Stefan Borgwardt; Margret Drewe; Rolf-Dieter Stieglitz; Anita Riecher-Rössler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-11-14       Impact factor: 5.270

5.  Kraepelin and Bleuler had it right: people with schizophrenia have deficits sustaining attention over time.

Authors:  Britta Hahn; Benjamin M Robinson; Samuel T Kaiser; Tatyana M Matveeva; Alexander N Harvey; Steven J Luck; James M Gold
Journal:  J Abnorm Psychol       Date:  2012-06-11

Review 6.  The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes.

Authors:  Raquel E Gur; Monica E Calkins; Ruben C Gur; William P Horan; Keith H Nuechterlein; Larry J Seidman; William S Stone
Journal:  Schizophr Bull       Date:  2006-11-13       Impact factor: 9.306

Review 7.  Sustained attention in psychosis: Neuroimaging findings.

Authors:  Gianna Sepede; Maria Chiara Spano; Marco Lorusso; Domenico De Berardis; Rosa Maria Salerno; Massimo Di Giannantonio; Francesco Gambi
Journal:  World J Radiol       Date:  2014-06-28

8.  Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU.

Authors:  J J Moyle; A M Fox; M Arthur; M Bynevelt; J R Burnett
Journal:  Neuropsychol Rev       Date:  2007-04-05       Impact factor: 7.444

9.  Functional magnetic resonance imaging (fMRI) of attention processes in presumed obligate carriers of schizophrenia: preliminary findings.

Authors:  Francesca Mapua Filbey; Tamara Russell; Robin G Morris; Robin M Murray; Colm McDonald
Journal:  Ann Gen Psychiatry       Date:  2008-10-03       Impact factor: 3.455

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.